What is the LUCIDITY Study?
The aim of the LUCIDITY Study is to assess the safety and effectiveness of an investigation drug in men and women with mild AD. The investigational drug will be compared with a placebo, which looks similar to the investigational drug but contains no active medication.
Who can take part in the LUCIDITY Study?
Approximately 180 people in 64 study center across the United States, Canaf=da, UK, Hungary, Belgium and Poland are expected to take part. You may be able to participate if you:
• Are under 90 years of age
• Have been diagnosed with AD
• Have a caregiver who can accompany you to the study center
There are other criteria that you will need to meet to qualify, which the study team will discuss with you.
How long will the LUCIDITY Study last?
The study is expected to last up to 36 weeks, during which you will be asked to attend the study center 5 times to undergo medical tests and assessments. The study is made up of three parts: